Jonathan Silberstein, MD
Chief of Urologic Oncology
Education & Affiliations
Biography
Dr. Silberstein completed medical school and was AOA at SUNY Upstate Medical University in 2004. He then went on to complete a residency in urology at the University of California in San Diego, where he published several articles and began his interest in urologic oncology. Following completion of his residency in 2010, he joined the fellowship program at Memorial Sloan-Kettering Cancer Center in New York. There he focused his academic pursuits in clinical trial design and implementation, and his clinical duties were devoted to operating and caring for patients with advanced urologic malignancies. He is published widely in the field of urologic oncology, with almost 50 peer-reviewed publications in the top journals in urology, as well as several book chapters. He has been the recipient of several grants and scholarships and has won multiple poster and essay competitions. He joined the Department of Urology at Tulane University Medical Center in 2013 as assistant professor and head the section of urologic oncology. He also has a joint appointment at the Veteran’s Affairs Hospital in New Orleans.
Jonathan Silberstein was recruited to join the faculty at Tulane University School of Medicine in 2013 from Memorial Sloan Kettering Cancer Center. He is the Chief of the Section of Urologic Oncology at Tulane and works closely with medical oncologists and radiation oncologists to find the correct individualized treatment for each patient and does not believe in a one size fits all approach. He treats and cares for all patients with localized and advanced urologic malignancies including prostate cancer, bladder cancer, kidney cancer and testis cancer. He is a leader in robotic surgery and has a great deal of experience performing robotic prostatectomies, robotic partial (trans and retroperitoneal) and radical nephrectomies and robotic cystectomies, with and without intracorporeal urinary diversion. Like any other surgical tool, he utilizes the robot when appropriate for the patient and uses open surgery when he believes that will result in a better oncologic outcome.
He was born and raised in New York City and earned his medical degree at SUNY Upstate Medical University in Syracuse, He completed his general surgery internship and his urology residency at the University of California in San Diego. After completing chief residency in San Diego he spent the next three years at Memorial Sloan Kettering Cancer Center, a premiere center in the United States for the management of surgical oncology. At Memorial Sloan Kettering Cancer Center he completed a fellowship and junior faculty position treating patients from around the globe with extremely complex and challenging cancer diagnoses. Following his residency, Dr. Silberstein completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center. He is the author of more than 60 peer-reviewed publications and several book chapters- demonstrating his commitment both to his patients and moving the field forward. He is also the winner of numerous awards from national and international meetings and is a reviewer and editor for several prominent urologic journals.
Contributions
Poon SA, Silberstein JL, Chen LY, Ehdaie B, Kim PH, Russo P. Trends in partial and radical nephrectomy: an analysis of case logs from certifying urologists. J Urol. 2013 Aug;190(2):464-9. doi: 10.1016/j.juro.2013.02.094. Epub 2013 Feb 27.
Silberstein JL, Poon SA, Maschino AC, Lowrance WT, Garg T, Herr HW, Donat SM, Dalbagni G, Bochner BH, Sandhu JS. Urinary diversion practice patterns among certifying American urologists. J Urol. 2013 Mar;189(3):1042-7. doi: 10.1016/j.juro.2012.08.240. Epub 2012 Sep 23.
Silberstein JL, Su D, Glickman L, Kent M, Keren-Paz G, Vickers AJ, Coleman JA, Eastham JA, Scardino PT, Laudone VP. A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons. BJU Int. 2013 Feb;111(2):206-12. doi: 10.1111/j.1464-410X.2012.11638.x.
Silberstein JL, Adamy A, Maschino AC, Ehdaie B, Garg T, Favaretto RL, Ghoneim TP, Motzer RJ and Russo P. Systematic classification and prediction of postoperative complications following nephrectomy in patients with metastatic renal cell carcinoma. BJU Int 2012 May 3.
Tarin TV, Power NE, Ehdaie B, Sfakianos J, Silberstein JL, Sjoberg DD, Dalbagni G, Bochner BH. Prospective evaluation of outcome of lymph node positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. E Urol, 61(5): 1025-30, 2012
Silberstein JL, Power NE, Vickers AJ, Savage C, Tarin TV, Favaretto RL, Su D, Kaag MG, Herr H, Dalbagni G. Renal Function and Oncologic Outcomes of Parenchymal Sparing Ureteral Resection versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. J Urol, 187(2): 1025-30, 2012
Silberstein JL, Vickers AJ, Power NE, Parra RO, Coleman JC, Pinochet R, Touijer KA, Scardino PT, Eastham JA, Laudone VP. Pelvic Lymph Node Dissection for Patients with Elevated Risk of Lymph Node Invasion during Radical Prostatectomy: Comparison of Open, Laparoscopic and Robot-Assisted Procedures. J Endourol, 2011 Nov 8. [Epub ahead of print]
Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA. Sci Transl Med, 3: 94ra72, 2011
Silberstein JL, Vickers AJ, Power NE, Fine SW, Scardino PT, Eastham JA, Laudone VP. Reverse stage shift at a tertiary care center: escalating risk in men undergoing radical prostatectomy. Cancer, 117: 4855, 2011
